Herzenberg L A, Tokuhisa T
J Exp Med. 1982 Jun 1;155(6):1730-40. doi: 10.1084/jem.155.6.1730.
The epitope-specific regulatory system selectively controls IgG antibody production to the individual (haptenic) determinants on a complex antigen. This system can be specifically induced to suppress primary and secondary IgG antibody responses to dinitrophenyl hapten (DNP) without interfering with antibody responses to epitopes on the carrier molecule on which the DNP is presented. Furthermore, once induced, it will specifically suppress responses to DNP presented on unrelated carrier molecules. Results summarized here obtained using widely different immunization conditions, and a variety of haptens and carrier molecules indicate that this regulatory system controls antibody production in most T-dependent antibody responses. Carrier-specific suppressor T cells (CTs) that arise shortly after priming with a carrier molecule such as keyhole limpet hemocyaninin (KLH) induce the epitope-specific system to suppress in situ and adoptive antibody responses to epitopes (e.g., DNP) presented subsequently on the priming carrier. These well-known regulatory T cells are commonly believed to regulate antibody production by interfering with carrier-specific help; however, by repeating the original CTs transfer experiments with additional controls that define the specificity of the mechanism mediating suppression in CTs recipients, we show that KLH-specific CTs regulate responses by inducing typical isotope- specific suppression for anti-DNP responses when the recipients are immunized with DNP-KLH. Thus, whether KLH-primed animals are immunized directly with DNP-KLH (KLH/DNP-KLH immunization sequence) or whether T cells from these animals are challenged with DNP-KLH in (nonirradiated)recipients, anti-DNP responses are persistently suppressed while anti-carrier responses proceed normally. The aqueous KLH-priming protocols usually used to generate CTs are marginally more effective in priming for in situ suppression-induction than the alum KLH-priming protocols commonly used to generate KLH-specific helper T cells and used here in KLH/DNP-KLH immunizations. Thus, studies presented show that priming with an antigenic (carrier) molecule simultaneously prepares the animal for the production of typical secondary (anamnestic) antibody responses to epitopes on the priming antigen and for the induction of epitope-specific suppression for antibody production to determinants presented subsequently on the same antigenic molecule. We discuss the mechanism(s) responsible for this duality and its significance for antibody responses in an accompanying publication that describes the bistable regulatory capabilities of the epitope-specific system.
表位特异性调节系统可选择性地控制针对复杂抗原上各个(半抗原性)决定簇的IgG抗体产生。该系统可被特异性诱导,以抑制对二硝基苯基半抗原(DNP)的初次和二次IgG抗体反应,而不干扰对呈现DNP的载体分子上的表位的抗体反应。此外,一旦被诱导,它将特异性抑制对呈现于不相关载体分子上的DNP的反应。此处总结的结果是在广泛不同的免疫条件下,使用多种半抗原和载体分子获得的,表明该调节系统在大多数T细胞依赖性抗体反应中控制抗体产生。在用诸如钥孔戚血蓝蛋白(KLH)等载体分子致敏后不久出现的载体特异性抑制性T细胞(CTs)诱导表位特异性系统,以原位抑制并过继性抑制对随后呈现于致敏载体上的表位(如DNP)的抗体反应。这些广为人知的调节性T细胞通常被认为通过干扰载体特异性辅助来调节抗体产生;然而,通过重复最初的CTs转移实验,并增加定义介导CTs受体中抑制作用机制特异性的额外对照,我们发现当受体用DNP-KLH免疫时,KLH特异性CTs通过诱导针对抗DNP反应的典型的同种型特异性抑制来调节反应。因此,无论用KLH致敏的动物是直接用DNP-KLH免疫(KLH/DNP-KLH免疫序列),还是来自这些动物的T细胞在(未受照射的)受体中用DNP-KLH攻击,抗DNP反应都会持续受到抑制,而抗载体反应则正常进行。通常用于产生CTs的水性KLH致敏方案在引发原位抑制诱导方面,比通常用于产生KLH特异性辅助性T细胞且在此处用于KLH/DNP-KLH免疫的明矾KLH致敏方案略微更有效。因此,所呈现的研究表明,用抗原性(载体)分子致敏同时使动物为产生对致敏抗原上的表位的典型二次(回忆性)抗体反应做好准备,并为诱导对随后呈现于同一抗原性分子上的决定簇的抗体产生的表位特异性抑制做好准备。我们在一篇伴随的出版物中讨论了负责这种双重性的机制及其对抗体反应的意义,该出版物描述了表位特异性系统的双稳态调节能力。